查詢結果分析
來源資料
相關文獻
- Use of Recombinant Epstein-Barr Virus Early Antigen for Detection of Antibody in Patients with Nasopharyngeal Carcinoma
- 鼻咽癌(Nasopharyngeal Carcinoma): Epstein-Barr病毒致病機制和治療策略之簡介
- Nasopharyngeal Carcinoma in Bunun Tribe of Taiwan
- Detection of IgA Against Epstein-Barr Virus Bzlf-1 Replication Activator (ZEBRA) in Sera of Nasopharyngeal Carcinoma Patients with a Recombinant ZEBRA Protein
- Expression of epstein-barr virus genome in nude-mouse-grown nasopharygeal carcinoma cells
- Orbital Invasion in Nasopharyngeal Carcinoma: Evaluation with Computed Tomography and Magnetic Resonance Imaging
- 上頜掀開術切除局部復發之鼻咽癌--三例報告
- 中醫脈診儀應用於鼻咽癌患者接受放射線治療全程之研究
- Detection of Human Papilloma Virus and Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma by Polymerase Chain Reaction
- 以螢光透視錄影吞嚥檢查評估鼻咽癌患者因放射線治療所致之吞嚥功能異常
頁籤選單縮合
題名 | Use of Recombinant Epstein-Barr Virus Early Antigen for Detection of Antibody in Patients with Nasopharyngeal Carcinoma=基因重組Epstein-Barr病毒早期抗原偵測鼻咽癌病人抗體 |
---|---|
作 者 | 劉明宗; 林龍參; 喻勇; 鍾從得; 許振益; 陳榮達; 鄭啟清; | 書刊名 | 中華醫學雜誌 |
卷期 | 57:1 1996.01[民85.01] |
頁次 | 頁7-15 |
分類號 | 416.879 |
關鍵詞 | 早期抗原; Epstein-Barr病毒; 鼻咽癌; Early antigen; Epstein-barr virus; Nasopharyngeal carcinoma; |
語文 | 英文(English) |
中文摘要 | 背景:鼻咽癌是大陸南方與臺灣常見癌症之一,研究報告指出它和Epstein-Barr病毒(EBV)有密切關係,病人血清及漱口水都有相當高的抗EB病毒的抗原。生物技術開發中心以基因重組技術製備EBV早期抗原,以用於偵測頭頸癌病人血清及漱口水之抗體。 方法:把EB病毒EA-D抗原的BMRFI基因殖入質體pDB185,再轉殖至包含對溫度敏感的lambda cI857抑制基因的大腸桿菌內。經熱處理後此菌於生長期中,會抑制了cI蛋白,因而增加EA-D蛋白的表現。經層柱法純化的EA-D蛋白,以SDS-PAGE定性的分子量為47kDa蛋白,再以抗EA的單株抗體或鼻咽癌病人的血清作西方墨點分析。我們利用純化過的EA-D做ELISA 來篩選129個頭頸癌病人血清與漱口水,24個非惡性腫瘤病人與44個正常對照組。 結果:顯示鼻咽癌病人血清比其他的頭頸癌與對照組有較高陽性率的EA IgA(69%)與EA IgG(91%)。同時鼻咽癌病人漱口水陽性率(34%)也比其他組(7-20%)為高。 結論:這些結果指出此種細菌合成的EA-D抗原可由鼻咽癌病人血清及單株抗體辨認。因此能應用於免疫酵素法篩檢有關EB病毒的疾病如NPC。 |
英文摘要 | Background: Nasopharyngeal carcinoma is one of the most common cancers in southern China and Taiwan. Serological studies revealed the close-relationship between NPC and Epstein-Barr virus (EBV). Elevated serum and saliva levels of anti-EBV antibodies are detected in patients with NPC. Therefore, Development Center for Biotechnology prepared the EBV-early antigen (EA-D) by recombinant DNA technique for screening the serum and throat washing samples from patients with head and neck cancers. Methods: The BMRF1 gene for EBV early antigen (EA-D) was placed into the plasmid pDB18, then transformed into an Escherichia coli strain containing the lambda cI857 temperature-sensitive repressor. Heat treatment of the transformant, at exponential growth phase, inactivated the cI protein and induced an over-expression of the EA-D protein. Next, the EA-D was purified by chromatography and characterized as a protein of molecular weight 47 kDa, by sodium dodecyl sulfate-polyacry lamide gel electrophoresis (SDS-PAGE) and Western blot analysis using monoclonal anti-EA antibody and sera from patients with nasopharyngeal carcinoma (NPC). Enzyme-linked immunosorbent assay (ELISA) with the purified EA-D antigen was used to screen 129 serum and throat washing (TW) samples from patients with head and neck tumors, 24 from patients with a nonmalignant disease and 44 from normal donors. Results: Experimental results indicated significantly higher positive rates of EA-D IgA (69%) and EA-D IgG (91%) in NPC sera than in the sera of patients with other head and neck tumors and normal controls. TW samples from patients with NPC also showed a higher positive rate (34%) than the other groups (7-20%). Conclusions: Results in this study demonstrate that the bacterially expressed EA-D antigen could be recognized by sera from patients with NPC and monoclonal antiEA antibody. Thus, it has potential use in ELISA for screening EBV-related diseases such as NPC. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。